Interesting Studies on

New Post Public Reply Private Reply Replies (0) Message Board
SouthernGold
723
Interesting Studies on Hydroxychloroquine

https://www.goodrx.com/blog/coronavirus-medic...treatment/

Study 1 – March 16, 2020

Researchers from China reported in a letter that over 100 people with COVID-19 have been treated with chloroquine. These patients had less severe disease and a shorter illness duration compared to those who did not receive chloroquine. However, results from these studies are not yet available, nor do we have a lot of information about the type of people who received this drug, or what dose they took and for how long.

Study 2 – March 20, 2020

A small study in France reported that people who got 600 mg of hydroxychloroquine had a lower amount of the virus (viral load) in the body. The problem with this study is that comparisons were made between patients at different hospitals. This makes it difficult to know if improvements were because of hydroxychloroquine or other things. And, of the 26 people who initially got hydroxychloroquine, 6 people (23%) had to stop treatment because of nausea, worsening disease, leaving the hospital, or death.

Six people in this study also received azithromycin (a common antibiotic) with hydroxychloroquine. These individuals had even lower viral loads at the end of the study compared to those who only got hydroxychloroquine. Research with more people is needed to help us understand whether improvements were because of the combination of medications or other factors. More information on safety is also important because taking azithromycin and hydroxychloroquine together can increase the risk of serious side effects, particularly irregular heart rhythm.

Study 3 – March 24, 2020

In a small Shanghai study of 30 people with COVID-19, half got 400 mg of hydroxychloroquine for 5 days while the other half did not. At the end of the study, 13 people (87%) who received hydroxychloroquine tested negative for COVID-19 compared to 14 people (93%) who also tested negative but did not receive the medication. Unlike the two studies above, this study suggests that hydroxychloroquine did not make a difference in recovery. Larger studies are needed to confirm the results.

Can hydroxychloroquine or chloroquine prevent or cure COVID-19?
At the time of this writing, hydroxychloroquine and chloroquine are not FDA-approved for the prevention or treatment of COVID-19. Additional data is needed to better understand the efficacy and safety of hydroxychloroquine and chloroquine for COVID-19. This is particularly important because current reports are based on a small number of patients, some who received dosages that were typically higher than what has been approved for other conditions.

Hydroxychloroquine and chloroquine have not yet been shown to prevent COVID-19 either in a community or hospital setting. In the studies cited above, patients received these medications in the hospital only after they were confirmed to have COVID-19. Additionally, the FDA’s Emergency Use Authorization for hydroxychloroquine and chloroquine are only for hospitalized patients who are unable to participate in a clinical trial.

Many clinical studies are currently underway to find a treatment for COVID-19, and the FDA is working with various government agencies, academic centers, and biopharmaceutical companies to expedite the process.

How can I get hydroxychloroquine or chloroquine?
Hydroxychloroquine and chloroquine both require a prescription from your doctor. Due to the recent increase in demand as a result of the COVID-19 pandemic, both medications are currently in short supply. This has made it difficult for patients with rheumatoid arthritis or lupus to get hydroxychloroquine, putting them at increased risk of complications.

Some states, such as North Carolina, Texas, and Idaho, recently restricted pharmacists from dispensing certain medications unless it is specifically being prescribed for an FDA-approved use. This is to help prevent medication stockpiling and potential drug shortages.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ribo Advances Lipid Disorder Strategy with SR122 Trial

Updated Category News Views 114

Ribo's New Chapter in Lipid Disorders For those keeping tabs on the cutting-edge of lipid research, Ribo’s latest maneuver isn't one to skim over. The company, hailing from both Suzhou and Sweden, just moved forward by submitting its Phase I Clinical Trial Application in Europe for a fascinating compound: SR122. This development isn’t just another filing; it marks a...

Continue Reading
Quest Diagnostics at Jefferies Conference: What’s Next?

Updated Category News Views 65

Quest Diagnostics Set for the Spotlight in London You're sipping your morning coffee when you hear that Quest Diagnostics (NYSE: DGX) is gearing up for a fireside chat in the UK's capital. Now, this isn't a random chit-chat we're talking about. Sam Samad, the man handling the books as their CFO, will be chatting it up at the Jefferies Global Healthcare Conference on...

Continue Reading
Burtch Works Joins Databricks: Fueling AI Success

Updated Category News Views 20

Game-Changer for AI Talent Market First off, let me tell you, in this data-driven world, finding solid AI talent is like hitting the jackpot. Burtch Works teaming up with Databricks? That's like leaping into a goldmine fully prepared. We're talking about forward-deployed engineers and specialized AI talent coming straight to your door. Closing the Impossible Talent Gap...

Continue Reading
Bimbo Bakeries Teamsters Gear Up for Strike in NJ

Updated Category News Views 102

A Brewing Storm at Bimbo Bakeries The morning air in East Brunswick fills with more than just the scent of fresh bread; there’s a tension you can slice through with a butter knife. Unwavering and fired-up, over 90 workers at Bimbo Bakeries have thrown their hats into the ring, ready to strike to protect something as sacred as the dough they churn—Teamsters' health...

Continue Reading
Zura Bio Faces Tough Road After Trial Failure

Updated Category News Views 155

Investor Dilemma: ZURA Takes a Nosedive November 9, 2026, wasn't a day to remember for anyone holding shares in Zura Bio. If ever there's a classic lesson in biotech investing's volatility, this is it: shares of Zura Biotech (NASDAQ:ZURA) cratered by about 72% after news broke that their much-hyped Phase 2 TibuSHIELD trial for tibulizumab hit the skids. For a company that...

Continue Reading
Gold.com Faces Fiduciary Investigation by Levi & Korsinsky

Updated Category News Views 56

Gold.com in Hot Water: What Shareholders Need to Know You ever wonder how firms like Gold.com find themselves in sticky situations before the ink's dry on the quarterly report? Well, strap in because Levi & Korsinsky, LLP is poking around to see if some officers and directors over there have taken a stroll down Breach Avenue. And let me tell you, if you're holding onto...

Continue Reading
Cloud Software Group's $2B Debt Offer Wraps Up

Updated Category News Views 115

Sizing Up Cloud Software Group’s Recent Maneuver Whoever thought navigating debt was a dull spectacle hasn’t kept up with Cloud Software Group's recent financial theatrics. With a $2 billion cap on the table, their cash tender offer for 9.00% Senior Secured Second Lien Notes due 2029 didn’t just happen; it paraded onto the financial stage and left a noteworthy...

Continue Reading
Inner City Visions Celebrates Two Decades of Impact

Updated Category News Views 126

Alfred Lomas' Transformation Fuels Lasting Change Once upon a time, Alfred Lomas was known as a brawler in the rough patches of South L.A., running with gangs and entangled in violence. But the story flipped, and instead of leaning into chaos, Lomas leaned into hope. That personal turnaround isn't just a headline—it's the crux behind Inner City Visions (ICV), the...

Continue Reading
Mesh Security Bolsters Team with Five Cybersecurity Experts

Updated Category News Views 252

New Blood in Cybersecurity: Mesh's Strategic Moves Ever felt like the cybersecurity world is in a constant game of catch-up? You're not wrong. In today's digital battleground, companies don't just need more tools—they need collective wisdom to bind it all together. And it seems like Mesh Security just caught onto that notion, stacking their deck with five new...

Continue Reading
Charitable Giving Turbocharges E-commerce Conversion Rates

Updated Category News Views 50

Charitable Giving: The Secret Sauce for E-commerce Success In an e-commerce arena teeming with bland sameness, charitable giving is proving to be a game-changing hook. That's right—brands partnering with Change and DailyKarma have found a magic formula where customers flourish and causes benefit. With over $7.4 million in donations spread across more than 3 million...

Continue Reading

Top 5 Most Recently Viewed Articles

BIGG Digital Assets Unveils the Intraverse Closed Beta Experience

Updated Category News Views 259

Transforming Digital Engagement with the Intraverse BIGG Digital Assets Inc. or "BIGG" (TSXV: BIGG, OTCQX: BBKCF) is at the forefront of innovation in the digital asset space. Recently, the company proudly announced the launch of a closed beta for the Intraverse, a cutting-edge platform designed to redefine how users interact within digital environments. This initiative...

Continue Reading
Melcor REIT and Developments Move Forward with New Arrangements

Updated Category News Views 202

New Support Agreements by Melcor REIT and Melcor Developments EDMONTON, Alberta – Melcor Real Estate Investment Trust, known as Melcor REIT, and Melcor Developments Ltd. have shared exciting news regarding their collaborative governance. The two entities have established voting support agreements with the Telsec Group and the FC Group, setting a positive trajectory for...

Continue Reading
Full Truck Alliance 2026 Q2 Results: A Mixed Bag

Updated Category News Views 152

Tale of the Tape: Full Truck Alliance Q2 2026 Full Truck Alliance (NYSE: YMM) just rolled out its second-quarter financials, and let me tell you, it's a mixed bag, folks. We're talking a 4.4% bump in net revenue climbing to RMB 3,381.6 million, that’s $498.4 million if you prefer Uncle Sam’s money. However, we’ve seen deeper profits with a net income spike of 6.3%....

Continue Reading
ABC Technologies Expands Lenders for TI Fluid Systems Acquisition

Updated Category News Views 246

ABC Technologies Acquisitions Limited Expands Lender Consortium ABC Technologies Acquisitions Limited, a subsidiary of ABC Technologies Inc., is making strides in its efforts to secure financing for the acquisition of TI Fluid Systems. As part of the ongoing arrangements, the company has recently bolstered its lender consortium to include several prominent financial...

Continue Reading
Pollo AI Unveils Game-Changing Tool for Video Consistency

Updated Category News Views 201

Introducing Pollo AI's Innovative Video Technology Pollo AI is making waves in the field of AI video generation with its groundbreaking feature known as the Consistent Character Video. This new tool enhances the ability to transform still images into high-quality AI videos while ensuring that characters, objects, and scenes remain consistent throughout each frame. The...

Continue Reading